Welcome to our dedicated page for ALSEN news (Ticker: ALSEN), a resource for investors and traders seeking the latest updates and insights on ALSEN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALSEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALSEN's position in the market.
Sensorion (ticker ALSEN) reported its 2020 financial results and outlined its 2021 outlook. The company raised €36 million to advance its SENS-401 therapy for hearing loss and expand its gene therapy pipeline via collaboration with Institut Pasteur. Key events include a delayed topline readout from the Phase 2 trial of SENS-401, now expected in Q4 2021, and a new trial for cisplatin-induced ototoxicity starting in H2 2021. The company ended 2020 with €62 million in cash, showing a net loss reduction from €12.1 million in 2019 to €9 million in 2020.